Rheumatol Ther: Long-Term Study of Secukinumab in Patients with Psoriatic Arthritis or Ankylosing Spondylitis

Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic immune-mediated diseases, and the pathogenesis of AS and PsA is multifactorial, genetic predisposition, environmental triggers A complex interaction with immune factors leads to a dysregulation of the immune syst.

Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic immune-mediated diseases, and the pathogenesis of AS and PsA is multifactorial, genetic predisposition, environmental triggers A complex interaction with immune factors leads to a dysregulation of the immune syst.

Psoriatic arthritis presents with variability in disease activity and clinical presentation, and is characterized by articular and extra-articular manifestations, including peripheral arthritis, axial involvement, tendinitis, dactylitis, and skin or nail disea.

Patients with AS and PsA often complain of pain, impaired physical function, and fatigue, which seriously affect their health-related quality of life (HR-Qo.

Secukinumab, a fully human monoclonal antibody that directly inhibits IL-17A, has been approved for the treatment of AS and PsA, and evidence from the clinical development program shows that Secukinumab has sustained efficacy and a favorable safety profi.

SERENA is an ongoing, longitudinal, real-world observational study involving patients with moderate-to-severe psoriasis, PsA, or .

The current interim analysis included 1004 patients with PsA or .

Two years after starting treatment, patients who continued to receive secukinumab showed high retention rates and a favorable safety profile with continued effica.

Source: Kiltz U, Sfikakis PP, Gaffney K, Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinum.

 leave a message here